Meeting
2023 ASCO Gastrointestinal Cancers Symposium
nITRO: A phase 2 study of perioperative liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) in patients with resectable pancreatic ductal adenocarcinoma (rPDAC).
Authors
Davide Melisi
Investigational Cancer Therapeutics Clinical Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;
Davide Melisi , Camilla Zecchetto , Valeria Merz , Giuseppe Malleo , Luca Landoni , Alberto Quinzii , Simona Casalino , Marina Gaule , Camilla Pesoni , Luca Casetti , Alessandro Esposito , Cristiana Piazzola , Mirko D'Onofrio , Riccardo de Robertis , Armando Gabbrielli , Claudio Luchini , Giovanni Butturini , Aldo Scarpa , Roberto Salvia , Claudio Bassi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03528785
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 701)
DOI
10.1200/JCO.2023.41.4_suppl.701
Abstract #
701
Poster Bd #
K8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
First Author: Sherise C. Rogers
Poster
2015 ASCO Annual Meeting
DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas—Final results.
First Author: Thomas Jens Ettrich
Poster
2015 Gastrointestinal Cancers Symposium
DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas—Final results.
First Author: Thomas Jens Ettrich